Edited Feb. 7th, 2019
This thread is dedicated to Urecholine (bethanechol). Several posts have been removed from the original version (see links below).
See the associated PSSD Lab posts on this topic:
Bethanechol (1/30/19): https://pssdlab.wordpress.com/2019/01/31/bethanechol/
Statement on Bethanechol (2/7/19): https://wordpress.com/post/pssdlab.wordpress.com/1829
- Ghost
Literature (Thanks to anacleta - from Wed Jan 09, 2019 12:26 pm)
Treatment of Antidepressant-Induced Sexual Dysfunction - 1998
https://webcache.googleusercontent.com/ ... clnk&gl=sm
"Bethanechol is a cholinergic agonist that has occasionally been useful in reversing sexual dysfunction associated with TCAs and MAOIs.[70,71,72,73] Typical doses are 10mg to 20mg as needed or 30mg to 100mg daily in a divided dose. Potential side effects with bethanechol include diarrhea, cramps, and diaphoresis. No reports have evaluated or suggested the efficacy of bethanechol for treating SSRI-induced sexual side effects."
Sexual side effects of antidepressant drugs - 2012
https://www.researchgate.net/publicatio ... sant_drugs
"Antidote or Agonist Approaches: ... cholinergic bethanechol [66,67]..."
66. Gross MD. Reversal by bethanechol of sexual dysfunction caused by anticholinergic antidepressants. Am J Psychiatry 1982;139:1193--4.
67. Segraves RT. Reversal by bethanechol of imipramine-induced ejaculatory dysfunction. Am J Psychiatry 1987;144:1243--4
BETHANECOL CHLORIDE FOR TREATMENT OF CLOMIPRAMINE-INDUCED ORGASMIC DYSFUNCTION IN MALES - 2004
https://pdfs.semanticscholar.org/0862/9 ... 565956.pdf
Bethanechol-induced increase in hypothalamic estrogen receptor binding in female rats is related to capacity for estrogen-dependent reproductive behavior. - 1988
https://www.ncbi.nlm.nih.gov/pubmed/2900667/
"Neuroactive agents associated with different neurotransmitter systems can modulate the number of hypothalamic estrogen binding sites. It has been demonstrated previously that the muscarinic cholinergic agonist, bethanechol, administered 30 min prior to in vitro estrogen receptor assays increases the concentration of hypothalamic estrogen binding sites by 30-35% in female rats. Bethanechol was without effect on male hypothalamic preparations. In order to investigate further this sex difference and in an attempt to determine a relationship between the modulation of estrogen binding sites and a sexually differentiated function, bethanechol was given to female rats rendered either anovulatory and capable of displaying lordosis or anovulatory and behaviorally insensitive to estrogen. The results showed that bethanechol significantly increased the number of estrogen binding sites in females capable of displaying lordosis but not in females which did not show this estrogen-dependent behavior. It is possible that the capacity for drug-induced modulation of estrogen binding sites could be related functionally to the ability to display lordosis behavior."